PK VITALITY

Their core work

PK VITALITY is a French medtech SME developing K'Watch Glucose, a smartwatch that continuously monitors blood sugar levels without needles or skin punctures. Their core technology is a minimally invasive biosensor embedded in a wearable device, targeting people with diabetes who need real-time glucose data to prevent dangerous hypoglycemic episodes. They progressed from a feasibility prototype to a full commercial development program entirely through EU SME Instrument funding, suggesting a product-first company using grant capital to bring a regulated medical device to market. Their work sits at the intersection of wearable electronics, biosensor chemistry, and clinical diabetes management.

What they specialise in

How they've shifted over time

PK VITALITY's H2020 trajectory is a textbook SME Instrument scale-up story rather than a topic pivot: they entered in 2017 with a Phase 1 feasibility grant to validate the K'Watch Glucose concept, then returned in 2020 with a Phase 2 grant nearly 46 times larger to execute full product development. The early project carried no structured keywords, reflecting the exploratory nature of the feasibility stage, while the later project crystallized around four precise terms — diabetes, glucose monitoring, hypoglycemia prevention, wearable — showing a sharpened clinical and commercial focus. There is no domain shift; instead, the evolution is one of depth: from "can this be built?" to "build it, validate it, and bring it to market."

PK VITALITY is moving toward regulatory submission and commercialization of a single flagship product; a future partner would most likely be a clinical validation site, a diabetes care provider, or a medical device distributor — not a research consortium.

How they like to work

PK VITALITY has acted exclusively as project coordinator across both H2020 grants, and the data shows zero recorded consortium partners — consistent with the solo-applicant model common in SME Instrument projects. This means they are a self-contained product company that uses EU funding to finance internal R&D milestones, rather than a collaborative research actor building networks. Anyone seeking to work with them should expect a vendor or licensing relationship rather than a co-investigator dynamic.

PK VITALITY has no recorded consortium partners from their H2020 participation, having pursued both grants as a solo SME applicant. Their European footprint is limited to their own operations in Paris; any external collaborations (clinical partners, subcontractors, distributors) are not visible in the CORDIS data.

What sets them apart

PK VITALITY occupies a very specific niche: a pure-play wearable CGM company that has twice convinced EU evaluators to fund the same product at progressively higher stakes, which signals genuine technical credibility in a heavily competitive space (competing with Dexcom, Abbott FreeStyle Libre, and others). Unlike academic groups working on glucose sensing in general, they are building one specific product for one specific patient population, which makes them a precise and low-ambiguity partner for anyone operating in diabetes care, connected health devices, or patient monitoring. Their value to a consortium is as a technology provider with a near-market device, not as a broad research partner.

Highlights from their portfolio

• K Watch Glucose (Phase 2)
  At EUR 2.29M, this is one of the larger SME Instrument Phase 2 awards in the digital health space, confirming both technical maturity and a credible commercial plan assessed by EU reviewers.
• KWatch Glucose (Phase 1)
  The 2017 feasibility grant launched the entire product trajectory, making it the founding proof-of-concept for a medical device that progressed to multi-million-euro development within three years.